<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renal toxicity of lithium</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renal toxicity of lithium</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renal toxicity of lithium</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edgar V Lerma, MD, FACP, FASN, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> ingestion in patients with bipolar (manic depressive) illness has been associated with several different forms of kidney injury [<a href="#rid1">1</a>]. Arginine vasopressin resistance (AVP-R, previously called nephrogenic diabetes insipidus) is the most common kidney side effect of lithium therapy [<a href="#rid2">2,3</a>].</p><p>The predominant form of chronic kidney disease associated with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> therapy is a chronic tubulointerstitial nephropathy [<a href="#rid4">4</a>]. Although the majority of studies show infrequent and relatively mild kidney function impairment attributable to lithium therapy, end-stage kidney disease (ESKD) secondary to lithium-associated chronic tubulointerstitial nephropathy does occur in a small percentage of patients [<a href="#rid3">3,5-8</a>]. Relatively less is known about potential glomerular toxicity of lithium, particularly the nephrotic syndrome. Additional kidney manifestations of lithium exposure include renal tubular acidosis and hypercalcemia. (See  <a class="medical medical_review" href="/z/d/html/320.html" rel="external">"Lithium poisoning"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ARGININE VASOPRESSIN RESISTANCE (NEPHROGENIC DIABETES INSIPIDUS)</span><span class="headingEndMark"> — </span>Normally, water permeability of principal cells in the collecting tubule is regulated by antidiuretic hormone (ADH). Aquaporin-2 water channels (AQP2), which normally reside in the endosomes of principal cells, move to and fuse with the luminal membrane under the influence of ADH, thereby allowing water to be reabsorbed down the favorable concentration gradient. (See  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Regulation of plasma tonicity'</a>.)</p><p>Chronic <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> ingestion can lead to resistance to ADH, resulting in polyuria and polydipsia in up to 20 to 40 percent of patients [<a href="#rid4">4,9</a>]. Lithium enters the principal cells of the collecting duct through epithelial sodium channels in the luminal membrane [<a href="#rid9">9,10</a>]. It then accumulates in these cells and interferes with the ability of ADH to increase water permeability. Several possible mechanisms may be involved [<a href="#rid2">2,9,11-14</a>].</p><p><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> may increase expression of cyclooxygenase-2 and therefore increase urinary prostaglandin E2 excretion by medullary interstitial cells [<a href="#rid13">13</a>]. These prostaglandins then act on principal cells to induce lysosomal degradation of AQP2 water channels and a decline in urine concentrating ability:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> may reduce <em>AQP2</em> gene transcription, an effect that is prostaglandin independent, leading to a further decrease in concentrating ability [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> induces collecting duct remodeling characterized by a decreased population of principal cells relative to the number of intercalated cells, a phenomenon that was previously presumed to be due to apoptosis [<a href="#rid11">11,12</a>]. However, lithium may actually lead to proliferation of principal cells, which then undergo cell cycle arrest [<a href="#rid15">15</a>]. This may also be responsible for the development of interstitial nephritis and renal fibrosis.</p><p></p><p>With chronic use in humans, arginine vasopressin resistance (AVP-R, previously called nephrogenic diabetes insipidus) often becomes irreversible. In one study, patients who had been on the drug for more than 18 years invariably had an irreversible defect [<a href="#rid12">12</a>].</p><p>Acute onset of nocturia is an important clue to the presence of AVP-R. The urine is normally most concentrated in the morning due to lack of fluid ingestion overnight; as a result, the first manifestation of a loss of concentrating ability is often nocturia.</p><p>It should not be assumed that polyuria in a patient taking <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is due to AVP-R. Both arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) and primary polydipsia have also been described in patients treated with lithium; they may be induced by lithium or reflect underlying psychiatric disease, particularly the use of psychotropic medications, which induce a dry mouth, thereby stimulating thirst and producing a picture of primary polydipsia [<a href="#rid4">4,16,17</a>].</p><p>Thus, a water restriction test may be helpful in establishing the correct diagnosis since the treatment of these disorders is different. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a> and  <a class="medical medical_review" href="/z/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults", section on 'Primary polydipsia due to psychosis'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Although usually at least partially reversible [<a href="#rid18">18</a>], the lithium-induced concentrating defect may be permanent after prolonged therapy [<a href="#rid4">4,19</a>]. When lithium-induced AVP-R is diagnosed, discontinuation of the drug may be appropriate. However, in many cases, the benefits of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> on mood stabilization and suicide prevention outweigh the risks [<a href="#rid20">20,21</a>]. For those patients who continue lithium therapy, we recommend the concomitant use of the potassium-sparing diuretic, <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>.</p><p><a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">Amiloride</a> inhibits the epithelial sodium channels in collecting tubule cells  (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 1</a>) and therefore should minimize further accumulation of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> (if lithium therapy is continued). The following data support the use of amiloride in patients with AVP-R who continue to use lithium:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">Amiloride</a> was given to nine patients who continued to take <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> despite the development of AVP-R [<a href="#rid10">10</a>]. After three to four weeks of therapy, mean urine volume fell significantly (from 4.7 to 3.1 liters per day), and urine osmolality increased significantly (from 228 to 331 mosm/kg). This effect persisted for at least six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a placebo-controlled crossover study, 11 patients with lithium-induced AVP-R were treated with 10 mg/day of <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> or placebo in random order for six weeks [<a href="#rid22">22</a>]. Amiloride therapy significantly increased the responsiveness of the urine osmolality to exogenous arginine vasopressin (165 percent increase in urine osmolality); no change in responsiveness to arginine vasopressin was seen with placebo.</p><p></p><p>However, <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> is likely to be effective only when there is a mild to moderate concentrating defect that is potentially reversible. The experience with amiloride has been disappointing in patients with severe disease (maximum urine osmolality below 200 mosmol/kg). In these patients, the tubular damage is often permanent, even if <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is discontinued [<a href="#rid4">4,19</a>]; as a result, diminishing lithium entry into the collecting tubular cells cannot improve concentrating ability.</p><p>If <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> therapy is given, serum <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> concentrations must be carefully monitored since diuretic-induced volume depletion may increase proximal sodium and lithium reabsorption. The ensuing fall in lithium excretion may then require a reduction in drug dose.</p><p>Other therapeutic options to manage polyuria in lithium-induced AVP-R are similar to those in other causes of AVP-R: a thiazide diuretic (to diminish distal water delivery or upregulate aquaporin receptors [<a href="#rid23">23</a>]) and a nonsteroidal antiinflammatory drug (NSAID; to decrease the synthesis of prostaglandins) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p>Another well-accepted regimen is the use of the combination of low-sodium diet and thiazide diuretics. Thiazides decrease urine volume and increase urine osmolality by producing a state of mild sodium depletion; this reduces distal tubule delivery of sodium and increases fractional water reabsorption in the collecting duct. As with the use of <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>, serum <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> concentrations <strong>must</strong> be closely monitored after initiation of therapy with a thiazide diuretic. (See  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p>Since most patients have only partial resistance to ADH, it is also possible that attaining supraphysiologic levels of ADH (by administering <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> [1-deamino,8-D arginine-vasopressin; dDAVP]) will attenuate the polyuria. The likelihood of success may be increased by combining desmopressin with an NSAID [<a href="#rid24">24</a>]. NSAID therapy alone also may be effective in selected patients [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p>The risk of hypernatremia and its complications is also considerable in these patients. This is particularly true in settings in which fluid intake is curtailed, during an acute illness, or when inadequate fluid resuscitation is given in those undergoing surgery.</p><p class="headingAnchor" id="H4"><span class="h1">RENAL TUBULAR ACIDOSIS</span><span class="headingEndMark"> — </span>The tubular defect in the distal nephron can also impair the ability to maximally acidify the urine. This is most often manifested as the incomplete form of type 1 (distal) renal tubular acidosis, in which the urine pH is persistently above 5.3 but the extracellular pH and bicarbonate concentration are within the normal range [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"</a> and  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">NEPHROTIC SYNDROME</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> has infrequently been associated with the nephrotic syndrome. Most cases are due to minimal change disease [<a href="#rid26">26,27</a>], but focal segmental glomerulosclerosis (FSGS) has also been described  (<a class="graphic graphic_picture graphicRef115166" href="/z/d/graphic/115166.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef115167" href="/z/d/graphic/115167.html" rel="external">picture 2</a>) [<a href="#rid6">6,28</a>].</p><p>The mechanism by which <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> leads to glomerular injury is not completely understood, but the course is highly suggestive of an etiologic role for lithium (ie, epithelial toxicity). Proteinuria generally begins within 1.5 to 10 months after the onset of therapy and, in minimal change disease, completely or partially resolves in most patients one to four weeks after lithium is discontinued [<a href="#rid26">26</a>]. In several patients, reinstitution of lithium led to recurrent nephrosis [<a href="#rid26">26,27</a>]. Corticosteroids have occasionally been required to induce remission; it is possible that the minimal change disease in such cases was unrelated to lithium [<a href="#rid26">26</a>].</p><p>The relationship to FSGS is less clear. In three patients, for example, cessation of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> did not lead to resolution of the disease [<a href="#rid28">28</a>], suggesting either no relation to lithium or possible secondary FSGS due to tubular injury induced by chronic lithium therapy. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Drugs and toxins'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Edema during the manic phase</span><span class="headingEndMark"> — </span>Occasionally, lithium-treated patients become edematous in the absence of overt kidney, hepatic, or cardiac disease [<a href="#rid29">29-31</a>]. How this occurs is not well understood, but two factors may contribute: a marked increase in sodium intake that may be induced in part by mania and perhaps a lithium-induced reduction in maximum sodium excretory capacity that is of no importance when sodium intake is relatively normal. Affected patients present with the unusual combination of edema plus high rates of urinary sodium excretion that can exceed 200 mEq/day [<a href="#rid30">30,31</a>]. Serum <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> concentrations may also fall below the therapeutic range at this time due to enhanced urinary lithium excretion. Volume expansion appropriately decreases the proximal reabsorption of sodium; lithium reabsorption also falls since it is reabsorbed via the same transporters as sodium [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CHRONIC INTERSTITIAL NEPHRITIS AND KIDNEY FUNCTION IMPAIRMENT</span><span class="headingEndMark"> — </span>Long-term <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> use is associated with chronic kidney disease that occasionally progresses to end-stage kidney disease (ESKD) [<a href="#rid6">6-8,32-39</a>]. As an example, in a large, retrospective, case-control study of Swedish adults, 1.8 percent of patients receiving kidney replacement therapy (KRT) for ESKD had a history of lithium exposure compared with 0.2 percent of patients without ESKD (odds ratio 7.8, 95% CI 5.4-11.1) [<a href="#rid40">40</a>].</p><p>Major risk factors for nephrotoxicity appear to be the duration of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> exposure and the cumulative dose [<a href="#rid7">7,32,41</a>]. Other risk factors include episodes of acute intoxication, increased age [<a href="#rid35">35,41</a>], other comorbid illnesses (eg, hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia), and concomitant use of other antipsychotic medications. The degree of kidney function impairment is variable [<a href="#rid16">16,35,36,41,42</a>].</p><p>Chronic interstitial nephritis usually presents as the insidious development of kidney function impairment, with normal to only a mild degree of proteinuria, often in the setting of arginine vasopressin resistance (AVP-R). The degree of interstitial fibrosis on kidney biopsy may be directly related to the duration and cumulative dose of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid7">7,41</a>]. Additional histologic lesions may be suggestive of chronic interstitial nephritis due to lithium:</p><p class="bulletIndent1"><span class="glyph">●</span>In experimental animals fed with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, there is a predominance of tubular lesions (ie, dilatation of tubules in the distal segments and collecting ducts); glomerulosclerosis tends to be a late event [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In humans, the presence of tubular cysts, which have been demonstrated to be of distal and collecting tubular origin, probably correspond to these tubular lesions [<a href="#rid6">6,44</a>].</p><p></p><p>Such microcysts have also been demonstrated on magnetic resonance imaging and ultrasonographic studies [<a href="#rid45">45,46</a>].</p><p>It has been suggested that 15 to 25 percent of patients develop a slowly progressive decline in glomerular filtration rate, which usually does not fall below 40 to 60 mL/min [<a href="#rid4">4,7,16,32</a>]. Progressive kidney failure with a serum creatinine concentration above 2 mg/dL (176 micromol/L) due solely to <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is uncommon [<a href="#rid42">42</a>] but can occur if lithium is continued after otherwise unexplained kidney function impairment has developed [<a href="#rid35">35,36</a>]. In a review of 74 patients with lithium-induced kidney function impairment from France, the mean loss of creatinine clearance was 2.3 mL/min per year, and, by age 65 years, 12 reached ESKD [<a href="#rid7">7</a>]. The average latent period between the onset of lithium therapy and ESKD was 20 years.</p><p>The course of the kidney disease after discontinuation of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is unpredictable. There may be some recovery of kidney function, particularly with correction of hypovolemia. Progressive kidney failure can occur among patients with significant kidney function impairment as is shown in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, seven out of nine patients with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> nephrotoxicity and a serum creatinine concentration of &gt;2.5 mg/dL (221 micromol/L) progressed to ESKD even after stopping lithium [<a href="#rid6">6</a>]. Among 10 patients who had an initial serum creatinine less than 2.5 mg/dL (221 micromol/L), only one developed ESKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study identified 18 patients with ESKD among 3369 lithium-treated patients in two regions of Sweden, a sixfold higher prevalence of disease than in the general population [<a href="#rid8">8</a>]. Of these, 13 had discontinued <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> for at least two years prior to starting dialysis. Eleven patients had serum creatinine concentrations greater than 1.4 mg/dL (125 micromol/L) at the time that lithium was discontinued; two patients had initial serum creatinine concentrations less than 1.1 mg/dL (100 micromol/L). However, both patients had even lower creatinine concentrations (less than 0.7 mg/dL [65 micromol/L]) when lithium was started, suggesting that a decline in kidney function had occurred with lithium.</p><p></p><p>Progressive kidney function impairment after cessation of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> may be due to secondary factors, such as systemic and intraglomerular hypertension, possibly resulting in secondary glomerulosclerosis [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">HYPERPARATHYROIDISM AND HYPERCALCEMIA</span><span class="headingEndMark"> — </span>Another complication of long-term therapy with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> carbonate is hyperparathyroidism, with associated hypercalcemia and hypocalciuria [<a href="#rid47">47</a>].</p><p>There are several mechanisms by which <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> may increase serum calcium levels:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing the threshold for the calcium-sensing mechanism within the parathyroid gland [<a href="#rid48">48</a>]. Thus, parathyroid hormone (PTH) secretion continues despite the presence of hypercalcemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inducing PTH overproduction via inhibiting the action of glycogen synthase kinase 3b (GSK-3b).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibiting calcium transport (influx) across cell membranes.</p><p></p><p>As hypercalcemia develops, it is further confounded by kidney failure and its progression, which leads to decreased urinary calcium excretion (hypocalciuria). Other findings associated with lithium-induced hypercalcemia/hyperparathyroidism include a normal serum phosphorus level and an elevated serum magnesium level.</p><p>There is a higher proportion of patients (33 percent) who develop parathyroid hyperplasia in those with lithium-induced hyperparathyroidism compared with the proportion of hyperparathyroidism affecting the general population [<a href="#rid47">47</a>]. This is probably the reason why acute withdrawal of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> does not necessarily translate into any significant change in serum calcium levels [<a href="#rid49">49</a>]. Because simple discontinuation of lithium carbonate therapy does not always lead to normalization of serum-intact PTH and calcium levels, surgical parathyroidectomy has been a common option in those patients.</p><p>Case reports have been published in which the use of <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">cinacalcet</a> [<a href="#rid47">47</a>], a calcimimetic, decreased or normalized the serum calcium, with some reduction of serum-intact PTH levels, similar to its effect in patients with primary hyperparathyroidism [<a href="#rid50">50,51</a>], thereby averting the need for surgical treatment. It is believed that cinacalcet can neutralize the effects of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> on the calcium-sensing receptor of the parathyroid gland. However, the mechanisms that underlie this effect remain undefined.</p><p class="headingAnchor" id="H9"><span class="h1">POSSIBLE INTERACTION WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS</span><span class="headingEndMark"> — </span>Some evidence suggests that there may be an adverse interaction between <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> and angiotensin-converting enzyme (ACE) inhibitors, leading to renal insufficiency that may be associated with lithium accumulation toxicity [<a href="#rid52">52,53</a>]. Although it is unclear whether this interaction is real, the serum creatinine concentration and lithium levels must be closely monitored if a patient on lithium is begun on an ACE inhibitor.</p><p class="headingAnchor" id="H10"><span class="h1">EXPERIMENTAL INVESTIGATIONS OF ALTERNATIVE TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>Caffeic acid phenethyl ester (CAPE), a known component of honeybee propolis, was protective against oxidative stress induced by reactive oxygen species (ROS), commonly observed in ischemia-reperfusion and toxic injuries. Used in experimental rat models, CAPE was shown to be protective against lithium-induced tubular damage and oxidative stress [<a href="#rid54">54</a>].</p><p><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC) has been demonstrated to be renoprotective and effective in preventing hypoperfusion and radiocontrast-induced nephropathy. Experimental Sprague-Dawley rats given NAC with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> had significantly lower percentages of tubular necrosis and tubular lumen obstruction [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1831946438"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H27106318"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> ingestion in patients with bipolar (manic depressive) illness has been associated with a variety of kidney diseases, particularly arginine vasopressin resistance (AVP-R, previously called nephrogenic diabetes insipidus) and, less frequently, chronic tubulointerstitial nephropathy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 20 to 40 percent of patients who chronically take <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> develop polyuria and polydipsia. In such patients, a water restriction test should be performed to establish the presence of AVP-R since patients with bipolar illness may also develop arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) and primary polydipsia. AVP-R appears to result from lithium accumulation in collecting tubule cells, which interferes with the ability of antidiuretic hormone (ADH) to increase water permeability. (See <a class="local">'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who develop AVP-R, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> therapy should be discontinued, if possible. However, for those patients in whom lithium therapy is absolutely necessary despite its kidney effects, concomitant <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> therapy to minimize lithium accumulation in collecting tubule cells is recommended. Amiloride is likely to be effective only when there is a mild to moderate concentrating defect that is potentially reversible. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy of the polyuria in lithium-induced disease is similar to that in other causes of AVP-R: a thiazide diuretic (to diminish distal water delivery or upregulate aquaporin receptors), a nonsteroidal antiinflammatory drug (NSAID; to decrease the synthesis of prostaglandins) provided kidney function is preserved, and a low-sodium diet. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since most patients have only partial resistance to ADH, it is also possible that attaining supraphysiologic levels of ADH (by administering <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> [1-deamino,8-D arginine-vasopressin; dDAVP]) will attenuate the polyuria. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> use is associated with the insidious onset of chronic kidney disease due to chronic interstitial nephritis in up to 15 to 20 percent of patients. Major risk factors for nephrotoxicity appear to be the duration of lithium exposure, the cumulative dose, and advanced age. The degree of kidney function impairment is generally relatively mild but may occasionally progress to end-stage kidney disease (ESKD). (See <a class="local">'Chronic interstitial nephritis and kidney function impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The course of the kidney disease after discontinuation of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is unpredictable. There may be some recovery of kidney function, particularly with correction of hypovolemia. However, progression of chronic kidney disease can occur. (See <a class="local">'Chronic interstitial nephritis and kidney function impairment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term therapy with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> may lead to hyperparathyroidism, hypercalcemia, and hypocalciuria. Discontinuation of lithium therapy does not always lead to normalization of parathyroid hormone (PTH) and calcium levels; thus, surgical parathyroidectomy is a common option in such patients. <a class="drug drug_general" data-topicid="8850" href="/z/d/drug information/8850.html" rel="external">Cinacalcet</a>, a calcimimetic, may also reduce PTH levels and a return the serum calcium to normal, thereby averting the need for surgical treatment. (See <a class="local">'Hyperparathyroidism and hypercalcemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less commonly, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> therapy can be associated with distal renal tubular acidosis, minimal change disease, focal segmental glomerulosclerosis (FSGS), and edema during episodes of mania. (See <a class="local">'Renal tubular acidosis'</a> above and <a class="local">'Nephrotic syndrome'</a> above and <a class="local">'Edema during the manic phase'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20:231.</a></li><li><a class="nounderline abstract_t">Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol 2010; 23 Suppl 16:S43.</a></li><li><a class="nounderline abstract_t">McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.</a></li><li><a class="nounderline abstract_t">Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10:329.</a></li><li><a class="nounderline abstract_t">Aurell M, Hestbech J. Lithium-induced uraemia. Lancet 1979; 1:882.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11:1439.</a></li><li><a class="nounderline abstract_t">Presne C, Fakhouri F, Noël LH, et al. Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 2003; 64:585.</a></li><li><a class="nounderline abstract_t">Bendz H, Schön S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77:219.</a></li><li><a class="nounderline abstract_t">Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.</a></li><li><a class="nounderline abstract_t">Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312:408.</a></li><li><a class="nounderline abstract_t">Ecelbarger CA. Lithium treatment and remodeling of the collecting duct. Am J Physiol Renal Physiol 2006; 291:F37.</a></li><li><a class="nounderline abstract_t">Christensen BM, Kim YH, Kwon TH, Nielsen S. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 2006; 291:F39.</a></li><li><a class="nounderline abstract_t">Kortenoeven ML, Schweer H, Cox R, et al. Lithium reduces aquaporin-2 transcription independent of prostaglandins. Am J Physiol Cell Physiol 2012; 302:C131.</a></li><li><a class="nounderline abstract_t">Li Y, Shaw S, Kamsteeg EJ, et al. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 2006; 17:1063.</a></li><li><a class="nounderline abstract_t">de Groot T, Alsady M, Jaklofsky M, et al. Lithium causes G2 arrest of renal principal cells. J Am Soc Nephrol 2014; 25:501.</a></li><li><a class="nounderline abstract_t">Bendz H, Aurell M, Balldin J, et al. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9:1250.</a></li><li><a class="nounderline abstract_t">Movig KL, Baumgarten R, Leufkens HG, et al. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry 2003; 182:319.</a></li><li><a class="nounderline abstract_t">Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 2005; 45:626.</a></li><li><a class="nounderline abstract_t">Shaikh BS, Nicholas GG, Miller FJ. Persistent nephrogenic diabetes insipidus after lithium carbonate. Ann Intern Med 1977; 86:446.</a></li><li><a class="nounderline abstract_t">Song J, Sjölander A, Joas E, et al. Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder. Am J Psychiatry 2017; 174:795.</a></li><li><a class="nounderline abstract_t">Werneke U, Ott M, Renberg ES, et al. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand 2012; 126:186.</a></li><li><a class="nounderline abstract_t">Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008; 3:1324.</a></li><li><a class="nounderline abstract_t">Kim GH, Lee JW, Oh YK, et al. Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol 2004; 15:2836.</a></li><li><a class="nounderline abstract_t">Stasior DS, Kikeri D, Duel B, Seifter JL. Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP. N Engl J Med 1991; 324:850.</a></li><li><a class="nounderline abstract_t">Allen HM, Jackson RL, Winchester MD, et al. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989; 149:1123.</a></li><li><a class="nounderline abstract_t">Wood IK, Parmelee DX, Foreman JW. Lithium-induced nephrotic syndrome. Am J Psychiatry 1989; 146:84.</a></li><li><a class="nounderline abstract_t">Alexander F, Martin J. Nephrotic syndrome associated with lithium therapy. Clin Nephrol 1981; 15:267.</a></li><li><a class="nounderline abstract_t">Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988; 84:951.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 1980; 62:193.</a></li><li><a class="nounderline abstract_t">Demers R, Heninger G. Pretibial edema and sodium retention during lithium carbonate treatment. JAMA 1970; 214:1845.</a></li><li><a class="nounderline abstract_t">Rose BD. An unusual disorder of salt and water balance. Kidney Int Suppl 1997; 59:S111.</a></li><li><a class="nounderline abstract_t">Schoretsanitis G, de Filippis R, Brady BM, et al. Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. Bipolar Disord 2022; 24:264.</a></li><li><a class="nounderline abstract_t">Kessing LV, Gerds TA, Feldt-Rasmussen B, et al. Use of Lithium and Anticonvulsants and the Rate of Chronic Kidney Disease: A Nationwide Population-Based Study. JAMA Psychiatry 2015; 72:1182.</a></li><li><a class="nounderline abstract_t">Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015; 386:461.</a></li><li><a class="nounderline abstract_t">Close H, Reilly J, Mason JM, et al. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS One 2014; 9:e90169.</a></li><li><a class="nounderline abstract_t">Roxanas M, Grace BS, George CR. Renal replacement therapy associated with lithium nephrotoxicity in Australia. Med J Aust 2014; 200:226.</a></li><li><a class="nounderline abstract_t">Kripalani M, Shawcross J, Reilly J, Main J. Lithium and chronic kidney disease. BMJ 2009; 339:b2452.</a></li><li><a class="nounderline abstract_t">Dineen R, Bogdanet D, Thompson D, et al. Endocrinopathies and renal outcomes in lithium therapy: impact of lithium toxicity. QJM 2017; 110:821.</a></li><li><a class="nounderline abstract_t">Pahwa M, Joseph B, Nunez NA, et al. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study. Bipolar Disord 2021; 23:715.</a></li><li><a class="nounderline abstract_t">Aiff H, Attman PO, Aurell M, et al. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol 2014; 24:540.</a></li><li><a class="nounderline abstract_t">Bocchetta A, Ardau R, Carta P, et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med 2013; 11:33.</a></li><li><a class="nounderline abstract_t">Waller DG, Edwards JG, Papasthatis-Papayanni S. A longitudinal assessment of renal function during treatment with lithium. Q J Med 1988; 68:553.</a></li><li><a class="nounderline abstract_t">Walker RG, Escott M, Birchall I, et al. Chronic progressive renal lesions induced by lithium. Kidney Int 1986; 29:875.</a></li><li><a class="nounderline abstract_t">Hansen HE, Hestbech J, Sørensen JL, et al. Chronic interstitial nephropathy in patients on long-term lithium treatment. Q J Med 1979; 48:577.</a></li><li><a class="nounderline abstract_t">Farres MT, Ronco P, Saadoun D, et al. Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 2003; 229:570.</a></li><li><a class="nounderline abstract_t">Karaosmanoglu AD, Butros SR, Arellano R. Imaging findings of renal toxicity in patients on chronic lithium therapy. Diagn Interv Radiol 2013; 19:299.</a></li><li><a class="nounderline abstract_t">Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis 2006; 48:832.</a></li><li><a class="nounderline abstract_t">Spiegel AM, Rudorfer MV, Marx SJ, Linnoila M. The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. J Clin Endocrinol Metab 1984; 59:354.</a></li><li><a class="nounderline abstract_t">Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240:357.</a></li><li><a class="nounderline abstract_t">Gregoor PS, de Jong GM. Lithium hypercalcemia, hyperparathyroidism, and cinacalcet. Kidney Int 2007; 71:470.</a></li><li><a class="nounderline abstract_t">Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008; 57:517.</a></li><li><a class="nounderline abstract_t">Lehmann K, Ritz E. Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment. Am J Kidney Dis 1995; 25:82.</a></li><li><a class="nounderline abstract_t">Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004; 52:794.</a></li><li><a class="nounderline abstract_t">Oktem F, Ozguner F, Sulak O, et al. Lithium-induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester. Mol Cell Biochem 2005; 277:109.</a></li><li><a class="nounderline abstract_t">Efrati S, Averbukh M, Berman S, et al. N-Acetylcysteine ameliorates lithium-induced renal failure in rats. Nephrol Dial Transplant 2005; 20:65.</a></li></ol></div><div id="topicVersionRevision">Topic 2358 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221853" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lithium and the kidney: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21170888" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265699" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lithium toxicity profile: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314489" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/86135" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lithium-induced uraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906157" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846754" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lithium-induced nephropathy: Rate of progression and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940841" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal failure occurs in chronic lithium treatment but is uncommon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384328" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lithium nephrotoxicity revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969096" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571597" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lithium treatment and remodeling of the collecting duct.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434572" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881002" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lithium reduces aquaporin-2 transcription independent of prostaglandins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495377" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408872" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lithium causes G2 arrest of renal principal cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7816284" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668407" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors for the development of lithium-induced polyuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806465" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Causes of reversible nephrogenic diabetes insipidus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/848808" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Persistent nephrogenic diabetes insipidus after lithium carbonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28595491" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22404233" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A decision analysis of long-term lithium treatment and the risk of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596116" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504936" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997862" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2719505" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492165" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lithium-induced nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7249424" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nephrotic syndrome associated with lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3129940" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Focal segmental glomerulosclerosis in patients receiving lithium carbonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7457166" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5537339" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pretibial edema and sodium retention during lithium carbonate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185116" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : An unusual disorder of salt and water balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34783413" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535805" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of Lithium and Anticonvulsants and the Rate of Chronic Kidney Disease: A Nationwide Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26003379" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24670976" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal failure in lithium-treated bipolar disorder: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24580527" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Renal replacement therapy associated with lithium nephrotoxicity in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578086" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lithium and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590494" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endocrinopathies and renal outcomes in lithium therapy: impact of lithium toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33548063" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503277" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : End-stage renal disease associated with prophylactic lithium treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23399351" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3252306" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A longitudinal assessment of renal function during treatment with lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3012187" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chronic progressive renal lesions induced by lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/538220" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chronic interstitial nephropathy in patients on long-term lithium treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14595154" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic lithium nephropathy: MR imaging for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439253" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Imaging findings of renal toxicity in patients on chronic lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060004" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6330156" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010382" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17315015" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Lithium hypercalcemia, hyperparathyroidism, and cinacalcet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18328354" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cinacalcet for the treatment of primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7810540" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086664" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Drug-induced lithium toxicity in the elderly: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132721" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lithium-induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546888" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : N-Acetylcysteine ameliorates lithium-induced renal failure in rats.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
